Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension
08 janv. 2025 08h00 HE
|
Mineralys Therapeutics, Inc.
– Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions associated with excess morbidity and mortality – –...
Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11 nov. 2024 16h05 HE
|
Mineralys Therapeutics, Inc.
– Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 – – Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering...
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
05 nov. 2024 16h05 HE
|
Mineralys Therapeutics, Inc.
RADNOR, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic...
Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024
04 nov. 2024 16h05 HE
|
Mineralys Therapeutics, Inc.
RADNOR, Pa., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic...
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
30 oct. 2024 08h00 HE
|
Mineralys Therapeutics, Inc.
– Topline data now anticipated in mid first half of 2025 – – Management to host virtual KOL event today to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal clinical...
Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024
22 oct. 2024 08h00 HE
|
Mineralys Therapeutics, Inc.
RADNOR, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic...
Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension
25 sept. 2024 08h00 HE
|
Mineralys Therapeutics, Inc.
– On track to announce topline data in Q1 2025 – – Virtual KOL event scheduled on October 30th to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal clinical program...
Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference
28 août 2024 08h00 HE
|
Mineralys Therapeutics, Inc.
RADNOR, Pa., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic...
Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
13 août 2024 16h05 HE
|
Mineralys Therapeutics, Inc.
– Advance-HTN trial is approximately 90% enrolled; trial is anticipated to deliver topline data in Q1 2025 – – Enrollment ahead of schedule in Phase 3 pivotal Launch-HTN trial and on track to deliver...
Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
05 août 2024 16h05 HE
|
Mineralys Therapeutics, Inc.
RADNOR, Pa., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic...